Zhejiang Haisen Pharmaceutical Co., Ltd. (SHE:001367)
China · Delayed Price · Currency is CNY 19.32
+0.60 (3.21%)
At close: Oct 28, 2026
SHE:001367 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
| 2,905 | 3,300 | 2,796 | 2,989 | - | - | |
Market Cap Growth | -19.57% | 18.01% | -6.46% | - | - | - |
Enterprise Value | 1,774 | 2,300 | 1,832 | 2,063 | - | - |
Last Close Price | 19.32 | 21.85 | 18.21 | 19.60 | - | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
PE Ratio | 19.93 | 24.29 | 22.82 | 28.56 | - | - |
PS Ratio | 5.23 | 6.20 | 5.93 | 7.52 | - | - |
PB Ratio | 1.83 | 2.21 | 2.08 | 2.39 | - | - |
P/TBV Ratio | 1.98 | 2.40 | 2.11 | 2.43 | - | - |
P/FCF Ratio | 18.43 | 131.00 | 27.31 | 128.99 | - | - |
P/OCF Ratio | 13.65 | 18.60 | 16.73 | 37.08 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.19 | 4.32 | 3.89 | 5.19 | - | - |
EV/EBITDA Ratio | 9.44 | 14.00 | 13.87 | 18.18 | - | - |
EV/EBIT Ratio | 11.09 | 16.13 | 15.70 | 20.45 | - | - |
EV/FCF Ratio | 11.26 | 91.29 | 17.89 | 89.04 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0 | 0.00 | 0.00 |
Debt / EBITDA Ratio | 0.04 | 0.04 | 0.06 | 0.00 | 0.01 | 0.01 |
Debt / FCF Ratio | 0.05 | 0.30 | 0.08 | 0.01 | 0.01 | 0.02 |
Net Debt / Equity Ratio | -0.71 | -0.70 | -0.76 | -0.75 | -0.52 | -0.57 |
Net Debt / EBITDA Ratio | -6.08 | -6.41 | -7.77 | -8.31 | -2.08 | -1.74 |
Net Debt / FCF Ratio | -7.17 | -41.83 | -10.02 | -40.72 | -4.50 | -2.77 |
Asset Turnover | 0.34 | 0.34 | 0.33 | 0.42 | 0.81 | 0.93 |
Inventory Turnover | 2.46 | 2.60 | 2.05 | 1.57 | 2.15 | 2.47 |
Quick Ratio | 10.35 | 10.06 | 9.33 | 12.90 | 3.53 | 2.46 |
Current Ratio | 11.38 | 11.01 | 10.31 | 14.95 | 5.35 | 3.51 |
Return on Equity (ROE) | 9.86% | 9.58% | 9.45% | 12.18% | 25.91% | 29.36% |
Return on Assets (ROA) | 6.05% | 5.72% | 5.16% | 6.62% | 12.59% | 15.61% |
Return on Invested Capital (ROIC) | 30.18% | 32.62% | 32.36% | 33.13% | 48.12% | 61.48% |
Return on Capital Employed (ROCE) | 9.90% | 9.40% | 8.60% | 8.00% | 21.80% | 28.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Earnings Yield | 5.02% | 4.12% | 4.38% | 3.50% | - | - |
FCF Yield | 5.42% | 0.76% | 3.66% | 0.78% | - | - |
Dividend Yield | 0.60% | 0.52% | 0.91% | 1.14% | - | - |
Payout Ratio | 11.87% | 12.84% | 27.74% | - | 0.66% | 17.48% |
Buyback Yield / Dilution | -1.64% | -2.15% | -9.03% | -22.74% | 0.02% | - |
Total Shareholder Return | -1.02% | -1.63% | -8.12% | -21.61% | 0.02% | - |